2023 USCHA

Registration Has Closed

USCHA is fast approaching, and we’re excited for our annual family reunion.  We thank all our session presenters for providing new opportunities for skills-building to address the HIV epidemic in our communities. We also thank all the USCHA partners and stakeholders that are actively involved in making this year’s theme of A Love Letter to Black Women come to life.

We’re grateful to USCHA’s Black Women’s Advisory Committee who has been working hard all year to curate a great conference experience for all.

Carmarion D. Anderson-Harvey
Clover Barnes
Gina Brown
Danielle Campbell
Ashley Coleman
Tori Cooper
Cecilia Dennis
Alicia Diggs
Dazon Dixon Diallo

Ingrid Floyd
Monica Johnson
Vanessa Johnson
Valencia Landry
Octavia Lewis
Tiommi Luckett
Johanne Morne
Kneeshe Parkinson
Kayla Quimbley
Venita Ray

Melanie Reese
Valerie Rochester
Beverly Ross
Linda Scruggs
Masonia Traylor
Dawn Trotter
Dr. Joyce Turner Keller
Dana Williams

New Hours for the Exhibit Hall

Make sure to include the exhibit hall in your plans for Tuesday, September 5.  This year the hall opens on Tuesday at 2pm and closes at 5pm on Thursday.  We’ll have an opening reception and DJ to get you started and our exhibitors will be waiting to greet you.  The exhibit hall is in the Liberty and Independence Ballrooms on the M4 Level.

Sweet Honey in the Rock

Sweet Honey in the Rock

Opening Plenary Session: Wednesday, September 6, 11:30am – 1:30pm

USCHA will send love to all the Black Women in our movement by sharing stories, honoring those that we’ve lost and showcasing current leaders on the frontlines. We will also give voice to the next generation that is ready to step up to end the HIV epidemic. The women of Sweet Honey in the Rock will give a soulful performance.

Federal Plenary Session: Saturday, September 9, 11:30am – 1:30pm

B. Kaye Hayes
Kaye Hayes
Dr. Robyn Neblett Fanfair
Dr. Robyn Neblett Fanfair
Ms. Yemisi Odusanya
Ms. Yemisi Odusanya
Dr. Mary Roary
Dr. Mary Roary
Dr. Janine Clayton
Dr. Namandjé N. Bumpus
Dr. Namandjé N. Bumpus

The Federal Plenary will include speakers from HHS, CDC, HRSA, NIH, SAMHSA and the FDA to update our movement on efforts to end the HIV epidemic. Make sure you’re there to hear from these fabulous leaders.

  • B. Kaye Hayes, Deputy Assistant Secretary for Infectious Disease, Director, Office of Infectious Disease and HIV/AIDS Policy (OIDP), Executive Director, Presidential Advisory Council on HIV/AIDS (PACHA)
  • Dr. Robyn Neblett Fanfair, Acting Division Director and Principal Deputy Director for the Division of HIV Prevention, Centers for Disease Control and Prevention
  • Ms. Yemisi Odusanya, Ending the HIV Epidemic Senior Advisor, HIV/AIDS Bureau, Health Resources and Services Administration
  • Dr. Mary Roary, Chief Equity Officer, Substance Abuse and Mental Health Services Administration
  • Dr. Janine Clayton, Director, NIH Office of Research on Women’s Health
  • Dr. Namandjé N. Bumpus, Chief Scientist, Food and Drug Administration

We have adjusted our COVID vaccination policy. Registrants will no longer be required to submit proof of vaccination. However, since numbers are starting to increase, we encourage everyone to receive the vaccination and associated boosters for the overall health of the conference.

Now in its 27th year, USCHA remains the conference to attend to experience the widest range of HIV-related topics, the most diverse attendees, the best exhibit hall and most unique plenary sessions.  We look forward to seeing you in DC.

Thank You to Our Sponsors

USCHA will not be possible without the generous support of our sponsors. We thank them for allowing us to provide scholarships, meals and support all of the logistics necessary to produce a great conference experience. Make sure to visit their booths in the exhibit hall.




V.i.i.V. Healthcare






Janssen Infectious Diseases & Vaccines


C.V.S. Specialty



Additional Sponsors

Broadway Cares/Equity Fights AIDS

Thera Technologies

Health Merch/Say It With A Condom

EMD Serono

Funding for this conference was made possible in part by grant number 1R13AI179319-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.